Dimensional Fund Advisors LP Lowers Stock Holdings in Phreesia, Inc. (NYSE:PHR)

Dimensional Fund Advisors LP trimmed its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 9.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 150,958 shares of the company's stock after selling 14,862 shares during the period. Dimensional Fund Advisors LP owned approximately 0.26% of Phreesia worth $3,799,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in Phreesia during the fourth quarter worth $30,000. BankPlus Trust Department acquired a new position in Phreesia during the fourth quarter worth $34,000. Venturi Wealth Management LLC acquired a new position in Phreesia during the fourth quarter worth $76,000. Smartleaf Asset Management LLC lifted its stake in Phreesia by 154.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company's stock worth $89,000 after purchasing an additional 2,090 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after purchasing an additional 459 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Stock Down 1.4%

NYSE:PHR traded down $0.37 during trading hours on Friday, hitting $25.34. The company's stock had a trading volume of 566,409 shares, compared to its average volume of 437,339. The stock has a market capitalization of $1.49 billion, a P/E ratio of -17.24 and a beta of 0.74. The stock has a fifty day moving average of $25.29 and a 200-day moving average of $24.94. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53.

Insider Activity at Phreesia

In other Phreesia news, COO Evan Roberts sold 3,519 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total transaction of $105,781.14. Following the transaction, the chief operating officer now owns 741,197 shares of the company's stock, valued at approximately $22,280,381.82. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP David Linetsky sold 4,499 shares of the firm's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total value of $106,761.27. Following the transaction, the senior vice president now directly owns 217,239 shares in the company, valued at approximately $5,155,081.47. The trade was a 2.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,260 shares of company stock valued at $1,406,251 over the last quarter. 5.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PHR shares. Piper Sandler restated an "overweight" rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Canaccord Genuity Group increased their price objective on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. KeyCorp reduced their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Finally, DA Davidson reduced their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has an average rating of "Buy" and a consensus target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.